NICE approves Enhertu for HER2-low metastatic breast cancer, offering new hope to patients
The UK health regulator NICE has reversed its earlier stance and approved the cancer drug Enhertu for NHS use, benefiting about 1,000 women with HER2-low advanced breast cancer.
NICE has overturned its 2024 rejection of the targeted therapy Enhertu, clearing it for NHS prescription to about 1,000 women with HER2-low advanced breast cancer. The change follows a newly reached commercial solution with manufacturers Daiichi Sankyo and AstraZeneca and revised cost-effectiveness thresholds. Clinical data show the drug can increase median survival to roughly two years versus less than a year and a half on standard chemotherapy.
Patients such as Paula Van Santen and Kathryn Hulland expressed renewed optimism about gaining more time with their families. Breast Cancer Now hailed the move as a milestone, while officials noted the decision arrives too late for many families who have already been denied the treatment.
Why it matters
The approval gives thousands of metastatic breast cancer patients access to a therapy that can significantly extend their lives.
In this story
